Mirtazapine for Poor Appetite in Hospitalized Older Adults With Major Neurocognitive Disorder or Oncologic Illness: A Retrospective Cohort Study
The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice · 2026-09 · 11 · 64-74
DOI: 10.1016/j.osep.2026.06.002 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice, 2026-09. Verfasst von Carlos Hallo Carrasco und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Objective
To evaluate appetite response and weight change after low-dose mirtazapine initiation for poor appetite in hospitalized older adults, including prespecified major neurocognitive disorder (MNCD) and oncology subgroups, and to compare initiators with matched controls.
Methods
Retrospective cohort study with a prespecified nested propensity score–matched comparison using risk-set sampling, conducted at three hospitals in an integrated health system (June 2024–June 2025). Participants were adults ≥65 years initiated on mirtazapine 7.5 mg (N=432); 110 initiators were matched 1:1 to contemporaneous controls. The primary outcome was clinician-documented appetite change, defined as increase in percentage of meals consumed or notation of improved eating. Secondary outcomes were weight change and oversedation prompting discontinuation. Matched outcomes were assessed from the index date through discharge.
Results
Appetite tracking occurred in 81.3% (351/432), with improvement in 22.5% (79/351). Mean weight change was −1.22±4.40 kg; oversedation prompted discontinuation in 6.3% (27/432). In the matched cohort, appetite improvement did not differ between initiators and controls (20% vs 23%; OR 0.89, 95% CI 0.43–1.82) and weight change was similar (mean difference 0.54 kg, 95% CI −0.58 to 1.66). MNCD was associated with lower improvement (OR 0.23, 95% CI 0.13–0.42) and oncology with higher improvement (OR 2.54, 95% CI 1.52–4.24).
Conclusion
In this retrospective cohort of hospitalized older adults, low-dose mirtazapine initiation was not associated with documented improvement in appetite or weight change compared with matched controls. These findings may not generalize to all hospitalized older adults and should be interpreted within the context of this study's cohort.
Zitieren
APA
Carrasco, C. H., Olson, C., Portley, M., Davidow, J., & Rojas-Velasquez, D. (2026). Mirtazapine for Poor Appetite in Hospitalized Older Adults With Major Neurocognitive Disorder or Oncologic Illness: A Retrospective Cohort Study. The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice, 11, 64-74. https://doi.org/10.1016/j.osep.2026.06.002
Vancouver
Carrasco CH, Olson C, Portley M, Davidow J, Rojas-Velasquez D. Mirtazapine for Poor Appetite in Hospitalized Older Adults With Major Neurocognitive Disorder or Oncologic Illness: A Retrospective Cohort Study. The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice. 2026;11:64-74. doi:10.1016/j.osep.2026.06.002
BibTeX
@article{Carrasco2026,
author = {Carrasco, Carlos Hallo and Olson, Courtney and Portley, Makayla and Davidow, Jennie and Rojas-Velasquez, Danilo},
title = {Mirtazapine for Poor Appetite in Hospitalized Older Adults With Major Neurocognitive Disorder or Oncologic Illness: A Retrospective Cohort Study},
journal = {The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice},
year = {2026},
volume = {11},
pages = {64--74},
doi = {10.1016/j.osep.2026.06.002}
}
EUVIMED